ArticleDrug design, development and therapy2026
Response Surface Methodology-Assisted Development and Validation of a Stability-Indicating HPLC-PDA Method for Quantification of Medroxyprogesterone Acetate in Microcrystals.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Reliable and stability-indicating analytical methods are required to support the development and quality control of Medroxyprogesterone Acetate (MPA), particularly in emerging solid-state pharmaceutical systems such as microcrystals. In this analytical method development and validation study, a stability-indicating reversed-phase high-performance liquid chromatography method with photodiode array detection (HPLC-PDA) was developed and validated using Response Surface Methodology (RSM) based on a Box-Behnken design for the quantitative determination of MPA in microcrystalline systems. RSM was applied to systematically evaluate the effects and interactions of critical chromatographic parameters, including methanol proportion, acid modifier concentration, and flow rate, enabling simultaneous optimisation of chromatographic responses related to sensitivity, retention behaviour, and peak symmetry. The optimised method demonstrated balanced chromatographic performance and was validated in accordance with the International Council for Harmonisation guideline Q2(R1). The method exhibited excellent linearity over the concentration range of 0.5-100 µg/mL (r = 0.9999), with accuracy ranging from 99.35% to 100.36% and precision expressed as relative standard deviation (%RSD) below 1.56%. The method also demonstrated adequate sensitivity, with limit of detection (LOD) and limit of quantification (LOQ) values of 0.045 µg/mL and 0.137 µg/mL, respectively, confirming its suitability for quantitative analysis. Forced degradation studies demonstrated that MPA was particularly susceptible to alkaline-thermal stress, resulting in the formation of distinguishable degradation-related peaks adjacent to the parent compound peak, supporting the stability-indicating capability of the method. Overall, the developed RSM-assisted HPLC-PDA method is suitable for routine analysis, stability studies, and formulation-oriented pharmaceutical quality control of MPA microcrystals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.